Veterinary Medicine

The International Association of Dental and Medical Disciplines®, a professional association of dentists and physicians, allows their doctor members to provide virtually just what the doctor ordered with Aetna and CIGNA’s decisions to reimburse doctors for online visits. IADMD® welcomes doctors to take this important step to move into the 21st century and out of the patient waiting room with no traffic jams, no long waits and no inconvenience which costs the same as regular office visits.

(PRWEB) February 28, 2008 -- The International Association of Dental and Medical Disciplines®, a professional association of dentists and physicians dedicated to patient advocacy and promoting their doctor-led version of universal health care, and its founder, Dr. John J. Ryan, DMD, offer the means for new online services aimed primarily at individuals who already are patients of the doctors.

Aetna and CIGNA have agreed to reimburse doctors for these visits and many more insurance companies are expected to follow. According to Dr. Melissa Welch, Aetna’s Northern California medical director, “People can wait a long time to get in to see their primary care doctor and longer for a specialist... to have immediate access is huge.” The Los Angeles Times reports, “The virtual visits are considered best for follow-up consultations and treatment for minor ailments such as colds and sore throats.”

“We are not an IT services company; we are a chartered professional society of doctors of all disciplines that gives our members free access to our IT department as a membership benefit. We are doctors working for doctors with insight to the entire claims process from the doctors’ perspective and we are operational with private HIPAA secure servers using 128 / 256 bit encryption that allows for private patient portals for virtual visits, and online bill pay, so effectively the virtual visit and co-pay can be one-in-done,” says Dr. Ryan, a dentist in East Hampstead, New Hampshire, and a Dental Examiner for the North East Regional Board of Dental Examiners. “These sessions are custom for each doctor member in accordance to their needs. We are working privately with each doctor member and their insurers to ensure reimbursement as agreed. As patient advocacy and privacy concerns are our number one concerns, teams of lawyers have been consulted on what is needed to ensure HIPAA compliancy. With legal direction in the infrastructure, these sessions are not susceptible to tampering or leakage that could affect a patient’s employability or insurability as it is not done via email. It uses the 128 / 256 bit encryption that allow for these private patient portals to show up only the doctor’s HIPAA secure server, thus, there is no access to the data via the World Wide Web. The only way the visit can be viewed is by the doctor logging onto the HIPAA secured server to which only the doctor has access.”

IADMD® calls this a major milestone for its members who already get a free doctor web site and free hosting, online bill pay, prescription refill service, and email services using HIPAA secure technology. IADMD will continue to provide virtual services linking patients with their dentists and physicians via a secure doctors web site system that allows them to coordinate individual patients’ care with online forms, such as virtual visits, tailored to each office’s needs.

About IADMD
IADMD is an association of doctors of all disciplines united to resolve overall health care with a doctor-led universal health care model that tunnels support through their doctors web sites. Dedicated to promote, protect, and advance human life, the IADMD® mission is to gain membership of doctors and with strength in numbers help their mission to put health care back in the hands of doctors. The doctors’ web sites help doctors and physicians put patient advocacy first and keep doctors in charge of medicine and patient care decisions while communicating with one another under one umbrella. The IADMD doctor-led universal health care plan recommends allowing unbiased teams of two physicians and two dentists from the association to stand before insurance commissioners in every state, to oversee and stop problems before they happen, and to intervene and correct when they are found to have gone awry. For more information on membership in IADMD, visit www.IADMD.org.

Media Contact: Tasha Pratt
Company Name: IADMD.org
Email: CustomerService (at) iadmd.org
Phone: (603) 382-7675

##

Drug-eluting stents, a breakthrough technology in the interventional cardiology field, are designed to reduce restenosis and thereby the requirement for repeated revascularizations. Innovative products and higher reimbursement are expected to pep up growth and expand drug-eluting stents market to corner US$5.7 billion by 2015. On the negative side, adverse effects such as in-stent thrombosis by the use of drug-eluting stents represents the most inhibiting market factor.

San Jose, CA (PRWEB) February 28, 2008 -- Increasing acceptance of stents as viable treatment option, expanding patient population seeking drug-eluting stents, and higher reimbursement coverage are key factors driving growth of drug-eluting stents. The global drug-eluting stents market is likely to grow and reach US$5.7 billion by 2015, as stated in a recent report published by Global Industry Analysts, Inc. The United States represents the leading regional market, capturing over 53% of worldwide sales. However, with the maturity of the DES market characterized by high penetration, the US is expected to witness the least growth through 2015. Additionally, recent incidents of adverse effects such as in-stent thrombosis developed as a result of using DES is expected to further dent the market growth. The European market has been relatively slow on the uptake mainly as a result of high price of stents and lower medical reimbursement rates in the region. Japan on the other hand, is a very new entrant into the market, the first DES product released only in late 2004.

Development of innovative treatment methods and preventive measures for coronary diseases, obesity, and diabetes are few factors influencing the long-term growth prospects of the drug-eluting stents market. However, adverse effects such as in-stent thrombosis by the use of drug-eluting stents, lower reimbursement levels, limited resources of national health care organizations in regions other than United States, arduous regulatory framework, high costs of the products and inflexible healthcare systems are some of the important issues that are inhibiting growth in the industry.

Drug-eluting stents registered significant growth in the recent past. However, recent incidents of adverse effects such as in-stent thrombosis is expected to significantly restrict future market growth. In-stent thrombosis is a common long-term adverse effect of DES where patients develop clots. Owing to the rise in in-stent thrombosis cases, major DES manufacturers such as J&J and Boston Scientific are experiencing hefty decline in sales. Although in-stent thrombosis cases occur rarely, they are highly fatal. On the contrary, bare-metal stents do not pose such threats thereby augmenting its usage in interventional management. The rise in in-stent thrombosis cases paves the way for anti-thrombotic therapies. Moreover, drug-eluting stents faces stiff competition from advanced and safer technologies such as tiny wire mesh tubes.

Major players in the marketplace include Abbott Vascular, AngioDynamics, Angiotech Pharmaceuticals, Boston Scientific, Biocompatibles International, Biosensors International, Cordis, Implant Sciences, Medtronic, MIV Therapeutics, and SurModics.

"Drug-Eluting Stents Market: A Global Strategic Business Report", published by Global Industry Analysts, Inc., provides a comprehensive review of market trends, product profile, recent developments, mergers, acquisitions, profiles of major players and other strategic industry activities. Analysis is presented for major geographic markets such as US, Japan, France, Germany, Italy, the UK, Spain, and rest of world. Analytics are presented for the period 2003 through 2015.

For more details about this research report, please visit http://www.strategyr.com/Drug-Eluting_Stents_Market_Report.asp.

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of over 60,000 smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Web Site http://www.StrategyR.com/

##

Atlanta, GA (PRWEB) February 28, 2008 -- NeboWeb, an Atlanta-based interactive marketing agency, announced the launch of the new ReGen Biologics corporate website powered by NeboWeb’s AJAX-based Content Management System. The almost effortless, yet powerful CMS includes intuitive content management features for quick and easy page creation. With integrated editing tools, file history views with rollback functionality, a newsroom / pressroom manager, multiple levels of users and permissions, and more, ReGen now has the ability to optimize content for search engines from within the CMS.

"ReGen is at the leading edge, making significant progress in orthopedics,” says Brian Easter, CEO of NeboWeb. “To be able to help facilitate, and distribute their groundbreaking work by incorporating our CMS is simply amazing. We’re proud to have been a part of it.”

ReGen Biologics is leading the way in tissue growth and repair. By reinforcing soft tissue with minimally invasive implants, ReGen’s surgical mesh is able to facilitate new tissue growth. ReGen is currently working to gain FDA clearance of its first surgical mesh product designed for use to reinforce meniscus tissue. The corporate site is being used in European countries to communicate breakthrough information to prospective patients, doctors, investors, as well as being a launching pad for their international product sites.

"This was a very involved project that required close work with the ReGen Biologics team,” says Adam Harrell, President of NeboWeb. “We completely overhauled their corporate identity, crafted a new image for their brand and developed a top-notch multi-lingual website that should easily provide for their future growth."

To learn more about the ReGen Biologics’ project visit http://www.neboweb.com/our-work.php?project_id=34.

About NeboWeb
NeboWeb is a full-service interactive marketing agency that offers a broad range of web presence solutions for large to enterprise level organizations. By delivering brilliant strategy through an experienced team of interactive experts, NeboWeb helps clients develop and implement successful online strategies. NeboWeb’s interactive marketing services range from complete interactive marketing engagements to standalone projects such as Web Design, Search Engine Optimization (SEO), Pay Per Click Management (PPC), Interactive Ad Creation, eCommerce Development, Online Public Relations and more. For more information on NeboWeb, visit www.NeboWeb.com or call 1-888-NeboWeb.

Contact NeboWeb:
Kimm Lincoln
Media Relations
NeboWeb
1.404.885.1201
klincoln@neboweb.com
http://www.neboweb.com

##

Carotid stents market, although in its infancy, is expected to witness gradual growth, driven primarily by the minimal-invasive nature of the method for treatment of carotid artery disease. World market for carotid stents in terms of revenues generated through carotid stent procedures is projected to total US$684 million by 2012.

San Jose, California (PRWEB) February 28, 2008 -- Reduced procedure time, fewer complications, and shortened duration of patient hospitalization are few factors contributing to the growing utilization of carotid stenting procedures. Advent of advanced technologies for carotid stent systems is expected to lead to higher prices for products, thereby enhancing the revenue generation capacity of the market. The carotid artery stents market is also expected to benefit significantly from the expanded coverage for asymptomatic patients.

Total number of carotid stent procedures in the world is estimated at over 90 thousand for 2007, as stated in a recent report published by Global Industry Analysts, Inc. The United States garners the lion's share of the global market. The region is expected to witness rapid growth in revenue generation associated with carotid stenting. The availability of clinical data supporting the efficacy of CAS procedures is expected to accelerate FDA approvals of various products, thereby facilitating their faster commercialization and adoption. Carotid stent market in Europe is expected to reach US$92 million by 2009.

The market currently faces impediments in the form of insufficient reimbursement coverage, absence of trained physicians for performing the procedure, and absence of long-term scientific evidence for their use. Undiagnosed status of a majority of patients also contributes to gradual penetration of carotid stenting. Moreover, the presence of proven and efficient surgical procedures for low-risk patients impedes the widespread prevalence of stenting. With several ongoing large-scale clinical trials set to reach their conclusion, the positive outcomes of these trials would boost the penetration rate for carotid artery stenting (CAS).

Key players profiled in the study include Abbott Vascular, Boston Scientific Corporation, ev3, Inc., Johnson & Johnson, Kensey Nash Corporation, and Medtronic, Inc. More than 50% of the US market is currently held by Boston Scientific and Abbott Vascular.

The report titled "Carotid Stents: A Global Strategic Business Report" published by Global Industry Analysts, Inc., covers major market dynamics, trends, issues, and competition pertaining to the market. The report enumerates recent developments, mergers, acquisitions and other strategic industry activities. Analytics are provided for the period 2004-2012 in terms of both number of procedures and revenues generated. Geographic markets analyzed include the United States, Europe, and Rest of World.

For more details of this research report please visit http://www.strategyr.com/Carotid_Stents_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of over 60,000 smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press@StrategyR.com
Web Site www.StrategyR.com

##

Record Growth Brings New Offices for Canadian Software Developer

Vancouver, BC (PRWEB) February 28, 2008 -- Cytiva Software Inc. (CRX:TSX-V), a leading provider of on-demand recruiting, performance management and educational administration software solutions, announced the relocation of its corporate headquarters in British Columbia to a new, larger facility in downtown Vancouver.

The Company is combining the offices of their current Burnaby headquarters and the West 3rd office of newly acquired one45 Software.

Cytiva’s revenues grew nearly 60% in 2007 and with the acquisition of one45 Software in December, the Vancouver headcount has doubled. The new facility, located at 850 West Hastings Street, 8th Floor, Vancouver, BC V6C 1E1, will house administrative, research and development and client services personnel.

The new facility is nearly triple the size of the previous space and is expected to easily accommodate existing employees as well as anticipated growth for the next few years. Cytiva anticipates another significant increase in revenue for 2008.

"The acquisition of one45 and the imminent launch of our new SonicPerform performance management software system has increased our headcount and revenue dramatically," said Jason Moreau, president and CEO of Cytiva Software. "The fact that we were able find a new building to accommodate our combined workforces that is close to the water, downtown amenities, transportation hub and the financial district is very encouraging."

In addition to its Vancouver headquarters, Cytiva maintains U.S. headquarters in Emeryville, CA, as well as satellite offices in Petaluma, CA, Marlborough, MA, Grand Rapids, MI, and Dallas, TX.

About Cytiva Software Inc.
Cytiva Software Inc. (CRX:TSX.V) provides innovative software and services to help mid-sized and Fortune 500 companies hire, manage and maximize their talent. Its flagship recruiting software, SonicRecruit, allows corporations to screen applicants, automate their recruiting departments, customize their corporate career sites and hire great people. This premier applicant tracking system improves recruiting effectiveness, speeding up the hiring process and reducing cost per hire. Over 220 organizations use Cytiva software, including Coca Cola Bottlers, Mazda, Ocean Spray, Restoration Hardware, Netflix and more. For more information, visit http://www.sonicrecruit.com.

CONTACT:
Ian Alexander
mediarelations @ sonicrecruit.com
510-984-1986

The TSX has not reviewed and does not accept responsibility for the accuracy or adequacy of this news release, which has been prepared by management.

Forward-looking Statements: This news release contains forward-looking statements related to the future financial condition and results of operations of Cytiva and One45, which Cytiva is proposing to acquire. These statements are based on current expectations and estimates about the human resources markets in which both Cytiva and One45 operate and management’s beliefs and assumptions regarding these markets. These statements are subject to important risks and uncertainties which are difficult to predict and assumptions which may prove to be inaccurate. Some of the factors which could cause results or events to differ materially from current expectations include but are not limited to: general economic conditions, market or business conditions; changing competitive environment; changing regulatory conditions or requirements; changing technology; and success in implementing productivity initiatives. In addition, the
acquisition of One45 by Cytiva is subject to various conditions, including a due diligence review, the entering into of a formal share purchase agreement and regulatory approval. Some of these factors are largely beyond the control of Cytiva. Should any factor impact Cytiva in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. All of the forward-looking statements made in this document are qualified by these cautionary statements, and there can be no assurance that the results or developments anticipated by Cytiva will be realized or, even if substantially realized, that they will have the expected consequences for Cytiva. Readers should not place undue reliance on any forward-looking statements. Further, Cytiva disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future events, or any other occurrence.

This press release was distributed through eMediawire by Human Resources Marketer (HR Marketer: www.HRmarketer.com) on behalf of the company listed above.

##